SOURCE: Amarillo Biosciences, Inc.
August 02, 2007 10:24 ET
Amarillo Biosciences Plans a Human Influenza Clinical Trial in Perth, Australia
AMARILLO, TX--(Marketwire - August 2, 2007) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR)
today announced that it has agreed to conduct human influenza research with
Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of
Biomedical, Bimolecular and Chemical Sciences, The University of Western
Australia. "We have been collaborating with Dr. Beilharz for more than 10
years," said Dr. Cummins, CEO of ABI. "During that time, Dr. Beilharz has
published 10 scientific papers or abstracts on the low-dose, oral use of
interferon. We are pleased to extend our research collaboration with Dr.
Beilharz. His exciting discoveries regarding how oral interferon can
protect against influenza are critically important as the world prepares
for the next influenza pandemic," said Dr. Joseph Cummins.
Recent publications from Freiburg, Germany by scientists (Grimm, et al.
Proceeding National Academy of Sciences, April 2007) and from (Tumpey, et
al. the Centers of Disease Control (CDC) and Prevention in Atlanta, J
Virology, July 2007) report that a single dose of interferon placed in the
nose of mice reduces mortality from 50% to 0% (CDC) or 100% to 0% (Germany)
in H5N1 ("Bird flu") influenza (CDC) or unique virulent influenza (Germany)
"We published earlier in 2007 that interferon in the mouth protects mice
against fatal influenza," said Professor Beilharz. "We used a concentration
of interferon similar to that used by CDC and also reported that a dosage
100 times less was also protective against fatal influenza infection in
mice. Our goal from new animal research is to determine the optimal dose
and timing of administration of oral interferon so we can more carefully
design human clinical trials. These human clinical trials will not only
address the influenza issue, but will also address a new approach to winter
colds and flu-like conditions," said Professor Beilharz.
Perth is a city in Western Australia with 2 million residents. The clinical
study will be conducted there in childcare workers, school teachers and
hospital workers who will be naturally exposed to infections of influenza
and other respiratory pathogens. Some subjects will take placebo daily
during the next "flu season" and others will take oral interferon at the
dosages covered by ABI's issued U.S. patents. Besides ABI's patented dose
formulation, two of ABI's issued U.S. patents have claims which directly
apply to the low-dose oral use of interferon for influenza.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global
partnership with the Hayashibara Group, which also holds 12% of Amarillo
Biosciences shares and has provided over $17.9 million in loans, grants and
equity investments. The Company's primary focus is extensive and ongoing
R&D into the use of low-dose, orally administered interferon as a treatment
for a variety of conditions, including Sjogren's syndrome, Behcet's
disease, and opportunistic infections in patients who are HIV positive. In
its 23-year history, ABI has invested nearly $38 million to establish oral
interferon as a therapeutic agent. The majority of those funds were
invested in clinical trials in an effort to achieve FDA approval for
interferon. Additional information is available on the ABI web site at
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon or the Company's other product
candidates and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission. In particular, see
"Item 1. Description of Business" of the Company's Form 10-KSB for the year
ended December 31, 2006.